The legal action centers on Embecta’s May 5, 2026, disclosure of second-quarter financial results. The company failed to meet its own performance guidance, reporting a revenue decline exceeding 14%—significantly worse than the initial forecast of flat growth or a 2% contraction. Management also lowered expectations for the remainder of the 2026 fiscal year, citing specific weakness in the firm's pen needle sales within the U.S. market.

Shareholders who acquired securities during the relevant class period have until August 17, 2026, to petition the court for appointment as Lead Plaintiff. Interested parties may reach out to Danielle Peyton at Pomerantz LLP via email at dpeytone@pomlaw.com or by calling 646-581-9980, extension 7980, to review the complaint and discuss potential participation in the litigation.